Related Experiment Video
Updated: Feb 11, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Overexpression of Lox in triple-negative breast cancer
Cornelia Leo1, Christine Cotic2, Victoria Pomp3
1Department of Gynecology, Kantonsspital Baden, Baden, Switzerland.
Background:
Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is associated with a poor prognosis and typically earlier onset of metastasis in comparison with other breast cancer subtypes. Since TNBC lacks the expression of estrogen and progesterone receptors and Her2 status is also negative, there is currently no target that can be used for systemic therapy. Epithelial-mesenchymal transition (EMT) plays an important role in tumor progression and metastasis. In this study, we examined a subset of EMT markers consisting of Snail, Twist-1 and Lox in TNBC and non-TNBC breast cancer subtypes and analyzed their expression pattern in regard to subtype, clinico-pathological parameters and prognosis.
Experimental Design:
We analyzed 659 breast cancer samples from two tissue microarrays. Breast cancer samples were categorized into two groups according to hormone receptor expression and Her2 status (n = 146 were triple negative, n = 513 were non triple-negative). Immunohistochemical expression of Snail, Twist-1 and Lox was semi-quantitatively analyzed using a three-tiered (weak-moderate-strong) scoring system. Results were statistically analyzed and correlated to clinico-pathological parameters and overall survival.
Results:
Strong overexpression of Lox was significantly higher in triple negative breast cancers when compared to non triple-negative breast cancers (p < 0.001). No difference was seen between the groups regarding Snail and Twist expression (p > 0.05). In addition, Lox expression was significantly stronger in poorly differentiated (G3) breast cancers (p < 0.001 for Lox).
Conclusions:
The EMT marker Lox has a differential expression pattern in breast cancer, being significantly overexpressed in triple negative breast cancers. We could not link this expression to prognosis, however, this marker might be explored in future studies as possible target for systemic therapy of TNBC.
Insights
Lysyl oxidase (Lox) is overexpressed in triple-negative breast cancer (TNBC), a subtype lacking targeted therapies. This finding suggests Lox may be a potential therapeutic target for TNBC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Triple-negative breast cancer (TNBC) comprises 15% of breast cancers, characterized by poor prognosis and early metastasis.
- TNBC lacks established therapeutic targets due to negative estrogen receptor, progesterone receptor, and Her2 statuses.
- Epithelial-mesenchymal transition (EMT) is a key process in tumor progression and metastasis.
Purpose of the Study:
- To investigate the expression patterns of EMT markers Snail, Twist-1, and Lox in TNBC and non-TNBC subtypes.
- To correlate the expression of these markers with clinico-pathological parameters and patient prognosis.
Main Methods:
- Analysis of 659 breast cancer samples from tissue microarrays, categorized into TNBC (n=146) and non-TNBC (n=513) groups.
- Semi-quantitative immunohistochemical analysis of Snail, Twist-1, and Lox expression using a three-tiered scoring system.
- Statistical correlation of marker expression with clinico-pathological data and overall survival.
Main Results:
- Strong Lox overexpression was significantly higher in TNBC compared to non-TNBC (p < 0.001).
- No significant difference in Snail or Twist-1 expression was observed between TNBC and non-TNBC groups (p > 0.05).
- Lox expression was significantly stronger in poorly differentiated (G3) breast cancers (p < 0.001).
Conclusions:
- The EMT marker Lox exhibits differential expression in breast cancer, with significant overexpression in TNBC.
- While Lox expression was not linked to prognosis in this study, it warrants further investigation as a potential therapeutic target for TNBC.
- This research highlights Lox as a promising candidate for future systemic therapy development in TNBC.
Related Concept Videos
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Negative Regulator Molecules
Positive, Negative, and Zero Work
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Positive and Negative Feedback Loops
Gram-negative Bacterial Protein Secretion Systems

